CytoMed deal

Grelan Pharmaceutical Co. Ltd. (Tokyo) received an exclusive license in Japan and other Asian countries to CMI-392, CytoMed's topical treatment for inflammation-related skin disorders. Grelan, which also received license rights for additional compounds selected by CytoMed, took an undisclosed equity position in the privately held Cambridge, Mass., company. ...